At Creative Biolabs, scientists are dedicated to bringing together years of valuable experience to help our clients shorten their research journey. We have a lot of experience in providing engineering ovarian cancer cell line CAOV3 for self-destruction purposes to reduce the overall project development timeline for our clients.

Background of Ovarian Cancer

Ovarian cancer is one of the most common malignancies in women over 40 years old, especially in developed countries. At present, the clinical treatment strategies for ovarian cancer mainly include chemotherapy, radiation therapy, surgery, targeted therapy, and combination therapy. Despite the creation of many innovations in the treatment of ovarian cancer over the past few decades, the 5-year relative survival rate remains less than 45%, and unlike other common malignancies, the proportion of women dying from OC has not substantially improved over time. Therefore, it is necessary and urgent to explore more novel therapies and new drugs.

Fig.1 Kaplan–Meier curves for overall survival of PPSC and ASOC. (Li, et al., 2021)

Ovarian Cancer Cell CAOV3

Human cancer cell lines are the most useful tool to study cancer biology, to develop and identify fresh treatments drug candidates, and means. Ovarian cancer cell line CAOV3 was developed from the primary tumor of a 54 years old ovarian adenocarcinoma caucasian female, with epithelial morphology. These cells express many tumor-associated markers, such as NB/70K, CA-125, Ba-2, and Ca-1. Caov-3 cells have a nonsense mutation in p53 and multiple copies of the OC oncogene PIK3CA. Additionally, they are sensitive to Vinblastine, Cisplatin, and Adriamycin.

Engineering Ovarian Cancer Cells CAOV3 for Self-destruction

Creative Biolabs is specialized in providing novel strategies for ovarian cancer immunotherapy study to both academia and biotech/pharmaceutical industries, we are committed to providing engineering ovarian cancer cell line CAOV3 for self-destruction. Which uses different means to transfect cytokines into ovarian cancer cell line CAOV3, and activates the immune system to destroy cancer cells.

With profound expertise and state-of-the-art technology platforms, we are committed to providing tailored services to each project to ensure that the objectives are met or exceeded. Creative Biolabs provides the following ovarian cancer research topic services for our clients, including but not limited to:

• Engineering Ovarian Cancer Cell OVCAR-3 for Self-destruction
• Engineering Ovarian Cancer Cells SK-OV-3 for Self-destruction
• Engineering Ovarian Cancer Cells IGROV1 for Self-destruction

For further details, please don't hesitate to contact us to discuss your project.

References

1. Luo, X.; et al. Shaping immune responses in the tumor microenvironment of ovarian cancer. Frontiers in Immunology. 2021, 12: 2383.
2. Li, X.; et al. Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database. Journal of ovarian research. 2021, 14(1): 1-0.

For Research Use Only | Not For Clinical Use